Scrambler Therapy® Technology MC-5A development in the US

Delta International Services & Logistics  main goal in the US is to create the conditions to fully implement the methodology in line with the original standards which are the only ones to guarantee a meaningful increase of success rates in hospitals and independent clinical trials. In the coming months this enterprise will create a series of excellence centers to guarantee an optimal quality system for ST usage including ST-NET support, a clinical “intelligent” network based on a dedicated software (STDM) designed exclusively for Scrambler Therapy®.  This software informs in real time the operator of possible critical features, and suggests most fit treatment protocols for any patient.

In the future some of these centers will be selected for the development of an adequate training and support system to optimize the users’ learning curve. These elements are necessary to reduce to a minimum operator dependent bias, that as recorded in statistic data in some independent clinical trials is currently very high, and well beyond the norm.

Scrambler Therapy scientific and clinical research (International Patent) is currently available in just one medical device labeled Scrambler Therapy® Technology MC-5A.  On May 22, 2015 the FDA authorized the marketing of the Scrambler Therapy® Technology MC-5A device (Clearance: # K142666 for Delta International Services & Logistics). This medical device has been developed in Italy by Prof. Giuseppe Marineo (International Patent) for the treatment of chronic neuropathic and oncologic pain resistant to opiates and other types of treatment, replacing the previous old version, known in the US as the Calmare® device.


Contact U.S. DIS&L Division:
Richard J. Erickson, North America Operations
Delta International Services & Logistics (USA)
6419 Hirondel St
Houston, TX 77087

Treatment using the Scrambler Therapy®  device avoids the harmful, potentially fatal, adverse side effects. The Scrambler Therapy®  device has been used to successfully treat thousands  patients worldwide, where it has been shown to be effective in treating neuropathic and oncologic pain. Scrambler Therapy is a stand-alone medical electroanalgesia device, and does not require combinations with other analgesic therapies.

DIS&L through its law firm is the only company authorized to sign international exclusive agreements in all international area, provide maintenance and distributor support for method usage training and other logistics needs. To request a national exclusive agreement the candidate distributor must have minimum requirements listed on the “Distributor Requirement” page.


Scrambler Therapy® if correctly used is a control tool for severe chronic neuropathic and cancer pain.  Scrambler Therapy is very effective, non-invasive and mainly to be used in ambulatory care and hospital facilities. If carried out correctly the analgesic effect during the treatment  is very rapid. In just a couple of seconds the pain perception completely disappears. This is true even in cases where pain is of high intensity and non responsive  or poorly responsive to opioids or other electro-analgesia devices such as TENS or implanted devices.

Clinical efficacy

Short and long term effects of a single treatment cycle depend on the type of pathology and other variables. In most cases of benign pain one treatment cycle is enough to produce pain relief for at least two months, but can even exceed 12 months if neuropathic damage is limited (mono-radicular) or the pathology has no evolution feature. Other variables that influence the treatment outcome are pharmaceutical interactions. Immediate analgesic efficacy during the treatment is a constant factor regardless of pathology and pain intensity.

For more information visit the official "Scrambler Therapy"® scientific and clinical information website


U.S. DIS&L Division